# GLP-1 Therapy Adverse Effects

Manage GLP-1 receptor agonist adverse effects by distinguishing expected dose-related gastrointestinal intolerance from pancreatitis, obstruction, gastroparesis, biliary disease, and perioperative aspiration risk. Escalation phase, severe persistent symptoms, and planned anesthesia require targeted medication and procedural decisions.

**Clinical question:** How should clinicians triage, mitigate, and escalate suspected adverse effects during GLP-1 receptor agonist therapy?

Updated: 2026-09-15T18:32:18.243948+00:00

## What matters in practice
- Nausea, vomiting, diarrhea, constipation, and dyspepsia are the predominant GLP-1–related adverse effects and are generally dose-related; assess severity before advancing the dose. [1][12][20]
- Persistent or severe abdominal symptoms should prompt evaluation for pancreatitis, bowel obstruction, gastroparesis, or biliary disease rather than attribution to routine treatment intolerance. [5][6][7][12]
- In a claims-based cohort of patients using liraglutide or semaglutide for weight loss, adjusted hazard ratios versus bupropion-naltrexone were 9.09 for pancreatitis, 4.22 for bowel obstruction, and 3.67 for gastroparesis; confidence intervals were wide. [7]
- Avoid GLP-1 receptor agonists in diabetic gastroparesis because they delay gastric emptying. [16]
- For elective procedures, most patients can continue GLP-1 therapy; defer elective procedures during dose escalation or active significant gastrointestinal symptoms, and use a 24-hour liquid diet for patients at higher risk. [22]

## Separate expected GI intolerance from potentially serious abdominal events

Use symptom trajectory and severity to determine whether dose management or urgent diagnostic evaluation is needed.

At every initiation and dose-escalation visit, ask specifically about nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal distension, and abdominal pain. These are common class effects; nausea, vomiting, diarrhea, and constipation are dose-related in GLP-1 therapy, while gastrointestinal effects are usually mild to moderate and transient. [1][12][20]

Do not label persistent or severe abdominal symptoms as routine GLP-1 intolerance without considering pancreatitis, bowel obstruction, gastroparesis, or gallbladder disease. In an obesity cohort without diabetes followed for a median of approximately 1 year, GLP-1 agonist use was associated with higher adjusted hazards of pancreatitis, bowel obstruction, and gastroparesis than bupropion-naltrexone; the observational design and wide confidence intervals require patient-level clinical assessment rather than automatic causal attribution. [6][7]

Review symptom onset against dose escalation, current dose, prior motility symptoms, and known gallbladder disease. A pre-treatment or interval assessment for gastroparesis and gallbladder disease is specifically recommended to reduce drug-related adverse-event risk; established diabetic gastroparesis is a reason to avoid GLP-1 receptor agonists because they delay gastric emptying. [12][16]
- Treat severe nausea, repeated vomiting or retching, marked bloating, or abdominal pain as a diagnostic trigger rather than a reason to proceed with routine dose escalation. [21]
- Ask whether constipation is accompanied by abdominal distension, pain, or vomiting; this pattern requires consideration of bowel obstruction. [5][6][7]
- Ask about early satiety, persistent postprandial fullness, recurrent vomiting, and prior diabetic gastroparesis before initiating or increasing therapy. [12][16]

*Symptom-based triage for GLP-1 receptor agonist adverse effects. [5][6][7][12][16][21]*

| Clinical pattern | Primary concern | Immediate next action |
| --- | --- | --- |
| Mild nausea, loose stools, constipation, or dyspepsia without severe pain or persistent vomiting | Common dose-related GI intolerance [1][12][20] | Reassess tolerability before further dose escalation; provide anticipatory counseling that symptoms are commonly transient. [12] |
| Persistent postprandial fullness, recurrent vomiting, or known diabetic gastroparesis | Delayed gastric emptying or gastroparesis [6][7][16] | Evaluate for gastroparesis; avoid GLP-1 receptor agonists in diabetic gastroparesis. [16] |
| Abdominal pain with prominent vomiting, distension, or constipation | Bowel obstruction [5][6][7] | Urgently evaluate for obstruction rather than continuing routine outpatient dose titration. [5][6][7] |
| Severe or persistent abdominal pain | Pancreatitis or biliary disease [5][6][7][12] | Evaluate promptly for pancreatic and biliary pathology; do not assume a benign medication effect. [5][6][7][12] |
| Severe nausea, vomiting, retching, bloating, or pain before anesthesia or deep sedation | Increased residual gastric contents and aspiration risk [21] | Delay an elective procedure until symptoms resolve; coordinate risk assessment with the procedural team. [21][22] |

## Manage common gastrointestinal effects without losing safety surveillance

Counsel before treatment and reassess symptoms at each dose transition.

Set expectations before initiation: nausea, diarrhea, dyspepsia, constipation, and vomiting are the principal adverse effects of GLP-1 receptor agonists, and most are mild to moderate and transient. Explicit counseling and reassurance can reduce treatment distress, but reassurance is inappropriate when symptoms are severe, persistent, or accompanied by concerning abdominal features. [12][20]

Use symptom burden to govern titration. Because gastrointestinal effects are dose-related and patients in the escalation phase are more likely to have delayed gastric emptying, do not advance a dose solely because a scheduled escalation date has arrived when clinically significant GI effects persist. [1][12][22]

For tirzepatide, reported adverse effects are similarly dominated by GI events; nausea occurred in 12% to 18% and diarrhea in 5% to 9% in the cited review. Patients should receive the same assessment for persistent vomiting, abdominal pain, or impaired oral intake as patients receiving a selective GLP-1 receptor agonist. [23]
- Document symptom severity and whether symptoms are improving, stable, or worsening before each planned dose increase. Dose-related symptoms that remain clinically significant favor delaying escalation. [1][12][22]
- Reassess hydration and oral intake when vomiting or diarrhea occurs, especially in patients at risk for dehydration or acute kidney injury. [8]
- Reevaluate the indication and continuation plan when GI effects impair adherence, nutrition, hydration, or safe perioperative care. [12][21][22]

*Medication-course features that change adverse-effect management. [1][12][22][23]*

| Feature | Why it matters | Management implication |
| --- | --- | --- |
| Dose escalation | GI effects are dose-related, and delayed gastric emptying is more likely during escalation. [1][22] | Assess symptoms before increasing the dose; defer elective procedures until escalation has passed and GI adverse effects have dissipated. [22] |
| Higher maintenance dose | Higher doses are associated with more GI side effects. [22] | For planned procedures, use a 24-hour liquid diet in patients at higher risk. [22] |
| Known diabetic gastroparesis | GLP-1 receptor agonists delay gastric emptying. [16] | Avoid GLP-1 receptor agonist therapy. [16] |
| Vomiting or diarrhea with reduced intake | Volume loss can contribute to dehydration and acute kidney injury. [8] | Assess volume status and renal risk rather than treating symptoms as inconsequential. [8] |

## Evaluate suspected pancreatitis, obstruction, gastroparesis, or biliary disease

The diagnostic target is determined by the symptom pattern, not by drug class alone.

Suspect pancreatitis when abdominal pain is severe or persistent and does not fit the usual self-limited nausea or dyspepsia pattern. The weight-loss claims analysis found an adjusted hazard ratio of 9.09 for pancreatitis with GLP-1 agonists versus bupropion-naltrexone, although the 95% confidence interval was 1.25 to 66.00; this is a safety signal requiring prompt clinical evaluation, not a quantified individual risk prediction. [7]

Suspect bowel obstruction when abdominal pain is accompanied by vomiting, abdominal distension, or severe constipation. In the same analysis, the adjusted hazard ratio for bowel obstruction was 4.22 (95% CI, 1.02-17.40). Evaluate the acute abdominal process urgently rather than continuing the agent through progressive symptoms. [7]

Suspect gastroparesis when postprandial fullness, nausea, vomiting, or impaired tolerance of oral intake persists beyond expected early treatment effects, particularly in a patient with diabetes or prior dysmotility. The adjusted hazard ratio for gastroparesis in the obesity cohort was 3.67 (95% CI, 1.15-11.90), and GLP-1 receptor agonists should be avoided in diabetic gastroparesis. [7][16]

Assess for gallbladder disease when symptoms localize to a biliary pattern or occur in a patient with known gallbladder disease. Although the cited obesity cohort did not find a statistically significant association with biliary disease (adjusted hazard ratio 1.50; 95% CI, 0.89-2.53), clinical evaluation remains appropriate because gallbladder disease is specifically identified as a condition to assess when managing GLP-1 adverse effects. [7][12]
- Do not use a temporal association with a dose increase to exclude obstruction, pancreatitis, or gastroparesis. [5][6][7]
- Coordinate urgent evaluation when severe pain, persistent vomiting, or obstructive symptoms occur; continued routine titration is not appropriate during an unresolved serious-event evaluation. [5][6][7]
- In patients with established diabetic gastroparesis, select an alternative glucose- or weight-management strategy rather than rechallenging with a GLP-1 receptor agonist. [16]

*Safety signals from a U.S. claims-based weight-loss cohort comparing liraglutide or semaglutide with bupropion-naltrexone. [7]*

| Outcome | Adjusted hazard ratio | Clinical interpretation |
| --- | --- | --- |
| Pancreatitis | 9.09 (95% CI, 1.25-66.00) [7] | Evaluate severe or persistent abdominal pain promptly; the imprecise estimate should not be used as an individual absolute-risk estimate. [7] |
| Bowel obstruction | 4.22 (95% CI, 1.02-17.40) [7] | Escalate evaluation for pain with vomiting, distension, or severe constipation. [7] |
| Gastroparesis | 3.67 (95% CI, 1.15-11.90) [7] | Evaluate persistent upper-GI motility symptoms; avoid GLP-1 therapy in diabetic gastroparesis. [7][16] |
| Biliary disease | 1.50 (95% CI, 0.89-2.53) [7] | The association was not statistically significant in this cohort; evaluate clinically compatible symptoms and known gallbladder disease. [7][12] |

## Manage GLP-1 therapy before anesthesia and deep sedation

Assess aspiration risk rather than automatically withholding therapy.

For elective surgery or deep sedation, most patients can continue GLP-1 receptor agonists. The decision should balance aspiration risk from delayed gastric emptying against risks of withholding therapy, including worsening glycemia in patients with diabetes. [22]

Identify patients at highest risk for delayed gastric emptying: those in dose escalation, those with active GI symptoms, and those receiving higher doses. The escalation phase typically lasts 4 to 8 weeks depending on the drug and indication; defer elective procedures until escalation is complete and GI adverse effects have dissipated. [22]

Patients with nausea, vomiting, abdominal pain, shortness of breath, or constipation should wait until symptoms resolve before an elective procedure. Patients receiving higher doses should follow a liquid-only diet for 24 hours before the procedure. [22]

When an elective procedure proceeds in a patient with concern for retained gastric contents, the earlier ASA guidance supports point-of-care gastric ultrasound when available and performed by an experienced clinician. If the stomach is full, ultrasound is inconclusive, or ultrasound is unavailable, consider delay or manage the patient with full-stomach precautions; discuss aspiration risk with the patient and procedural team. [21]
- Screen for GI symptoms during preoperative medication reconciliation, not only for whether the GLP-1 agent was taken. Active symptoms predict increased residual gastric contents. [21]
- Defer elective procedures during active dose escalation when GI symptoms remain present. [22]
- For urgent procedures in a patient with suspected delayed gastric emptying, coordinate anesthesia planning around aspiration precautions rather than relying on an elective withholding schedule. [21]

*Elective-procedure approach for patients receiving GLP-1 therapy. [21][22]*

| Periprocedural finding | Recommended action | Rationale |
| --- | --- | --- |
| No elevated GI-risk features | Continue GLP-1 therapy for most patients. [22] | Withholding must be balanced against risks such as hyperglycemia. [22] |
| Dose-escalation phase with ongoing GI effects | Defer elective surgery until escalation is complete and GI symptoms dissipate. [22] | Escalation generally lasts 4-8 weeks and is associated with greater delayed-gastric-emptying risk. [22] |
| Nausea, vomiting, abdominal pain, dyspnea, or constipation | Delay elective surgery until symptoms resolve. [22] | Symptoms identify higher risk for delayed gastric emptying and retained gastric contents. [21][22] |
| Higher-dose therapy | Use a liquid-only diet for 24 hours before the procedure. [22] | Higher doses are associated with more GI adverse effects. [22] |
| Medication not withheld under earlier ASA pathway and no symptoms | Use full-stomach precautions or assess gastric volume by ultrasound when expertise is available. [21] | Full or indeterminate gastric findings warrant delay consideration or full-stomach management. [21] |

## Build adverse-effect surveillance into prescribing and follow-up

A structured symptom review reduces unsafe escalation and improves procedural coordination.

At initiation, document baseline constipation, nausea, vomiting, postprandial fullness, prior gastroparesis, and gallbladder disease. Reassess these symptoms during escalation because early treatment is the period of greatest concern for delayed gastric emptying before procedures. [12][22]

Counsel patients to report severe or persistent abdominal pain, repeated vomiting, abdominal distension, or inability to maintain oral intake promptly. These findings redirect management from routine adverse-effect counseling to evaluation for pancreatitis, obstruction, gastroparesis, dehydration, or biliary disease. [5][6][7][8][12]

Ask patients to notify procedural teams that they use a GLP-1 agent before anesthesia or deep sedation. Preoperative planning should include current dose, whether they are in escalation, and active GI symptoms; these details determine whether therapy continues, a 24-hour liquid diet is used, or elective care is deferred. [21][22]
- Before each escalation: document current GI symptoms, oral intake, hydration concerns, and new abdominal pain. [1][8][12]
- Before an elective procedure: document agent class, dose phase, presence of nausea, vomiting, abdominal pain, constipation, or bloating, and whether the patient is receiving a higher dose. [21][22]
- For patients with diabetes, involve the clinician managing glycemia when perioperative medication changes are contemplated because withholding can increase blood glucose. [22]

## Common questions

### Should GLP-1 therapy be routinely held before elective surgery?

No. Current multisociety guidance states that most patients can continue therapy. Defer elective procedures during dose escalation or active GI symptoms, and use a 24-hour liquid diet for higher-dose patients; balance withholding against hyperglycemia risk. [22]

### When should GLP-1 therapy be avoided for motility symptoms?

Avoid GLP-1 receptor agonists in diabetic gastroparesis because they delay gastric emptying. Persistent postprandial fullness, nausea, or vomiting during therapy should trigger evaluation for gastroparesis rather than routine dose escalation. [16][7]

## References
1. Elecoglipron, an oral small molecule GLP-1 receptor ... — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00802-0/fulltext
2. Balancing the benefits and risks of GLP-1 receptor agonists — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00239-7/fulltext
3. GLP-1 receptor agonists and next-generation incretin ... — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02105-1/fulltext
4. The expanding role of GLP-1 receptor agonists: a narrative ... — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2825%2900295-0/fulltext
5. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2810542
6. Gastrointestinal Adverse Events in Patients Taking GLP-1 Agonists for Weight Loss | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/nejm-jw.NA56649?show-author=true&author-id=AU039
7. GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients — www.bmj.com — https://www.bmj.com/content/383/bmj.p2330
8. Comprehensive Management of Cardiovascular Risk Factors for ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001040
9. Mitigating Risk of Kidney Dysfunction After Heart Transplantation ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.125.013747?doi=10.1161%2FCIRCHEARTFAILURE.125.013747
10. Glucagon‐Like Peptide‐1 Receptor Agonists and Cardiovascular ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.125.047893
11. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664
12. ESI Clinical Practice Guidelines for the... : Indian Journal of Endocrinology and Metabolism — journals.lww.com — https://journals.lww.com/indjem/_layouts/15/oaks.journals/downloadpdf.aspx?an=02223308-202507000-00002
13. A Systematic Review Identifying Critical Evidence... : Obesity Reviews — journals.lww.com — https://journals.lww.com/00134512-202606000-00007
14. What obgyns need to know about GLP-1 receptor... : Current Opinion in Obstetrics & Gynecology — journals.lww.com — https://journals.lww.com/10.1097/GCO.0000000000001116
15. Prognostic benefit of glucagon-like peptide-1 receptor agonists ... — academic.oup.com — https://academic.oup.com/ehjcvp/article/11/4/324/8019778
16. Diabetic Gastroparesis | Endocrine Reviews - Oxford Academic — academic.oup.com — https://academic.oup.com/edrv/article/40/5/1318/5487986
17. Pneumatosis intestinalis in a patient treated with a glucagon-like ... — academic.oup.com — https://academic.oup.com/jcemcr/article-pdf/4/3/luag019/67089749/luag019.pdf
18. evolving field of nephrology: what comes next? A report from the ... — academic.oup.com — https://academic.oup.com/ckj/article/19/5/sfag136/8664055
19. Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2451847626000175
20. Brief Review: Commonly Used Non-Insulin Glucose-Lowering ... — diabetesjournals.org — https://diabetesjournals.org/books/book/59/chapter/5536558/Brief-Review-Commonly-Used-Non-Insulin-Glucose
21. American Society of Anesthesiologists Consensus-Based Guidance ... — www.asahq.org — https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
22. New Multi-Society GLP-1 Clinical Practice Guidance Released — www.asahq.org — https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
23. Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide ... — diabetesjournals.org — https://diabetesjournals.org/clinical/article/41/3/367/148555/Tirzepatide-A-Novel-Glucose-Dependent
24. 8. Obesity and Weight Management for the Prevention and ... — diabetesjournals.org — https://diabetesjournals.org/care/article/49/Supplement_1/S166/163915/8-Obesity-and-Weight-Management-for-the-Prevention

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.